Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Brain Res Bull. 2017 Jun 23;134:38–46. doi: 10.1016/j.brainresbull.2017.06.016

Fig. 2. Proliferation of NSPCs is reduced following αCT1treatment.

Fig. 2

Exposure of NSPCs to selective inhibitor αCT1 (d–f) reduces BrdU incorporation in a dose dependent manner following 24 hour incubation compared to the control Reverse control peptide (a–c). (g) Quantified data showing a significant reduction in the percentage of BrdU-positive cells at 37.5 and 75 μm αCT1 exposure compared to Reverse. Non-specific effects of Reverse at 150 μm were also seen. (h) Quantified data showing no changes in NSPC proliferation are evident at 8 hours of αCT1 treatment. *P<0.01; ***P<0.001 compared to Reverse control peptide.